Journal of Pharmaceutical Care (Oct 2022)

A Case Report of Three Guillain-Barré Syndrome During SARS-CoV-2 Pandemic: Promising Outcome in a Patient with History of Multiple Sclerosis

  • Amir ali Ghahremani,
  • Amir Bigdeli,
  • Davoud Salarbashi,
  • Pouyan Shakouri,
  • Sepideh Elyasi

DOI
https://doi.org/10.18502/jpc.v10i3.10800
Journal volume & issue
Vol. 10, no. 3

Abstract

Read online

Neurologic complications in patients with coronavirus disease 19 (COVID-19) are common particularly in hospitalized patients. Guillain–Barré syndrome (GBS) is a rare complication of COVID-19. Most patients with GBS and COVID-19 presented with progressive, ascending limb weakness evolving over one to four days. There are some reported cases of GBS, mostly in form of case reports or case series, and also a comprehensive review on this topic. However, none of these cases experienced multiple sclerosis (MS) as an underlying disease. So, in this manuscript we reported three cases of COVID-19 induced GBS; one of them with history of MS and promising outcome after receiving five session of plasmaphresis and corticosteroid therapy.

Keywords